Literature DB >> 31992098

Modified CLL International Prognostic Index (CLL-LIPI) using lymphocyte doubling time (LDT) in place of IgHV mutation status in resource-limited settings predicts time to first treatment and overall survival.

Deepesh P Lad1, V Tejaswi1, Nishant Jindal1, Pankaj Malhotra1, Alka Khadwal1, Gaurav Prakash1, Arihant Jain1, Sreejesh Sreedharanunni2, Manupdesh Singh Sachdeva2, Shano Naseem2, Neelam Varma2, Subhash Varma1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 31992098     DOI： 10.1080/10428194.2020.1719099

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  3 in total

1.  Lymphocyte doubling time in chronic lymphocytic leukemia modern era: a real-life study in 848 unselected patients.

Authors:  Tycho Baumann; Riccardo Moia; Gianluca Gaidano; Julio Delgado; Adalgisa Condoluci; Neus Villamor; Anil Babu Payedimarri; Dolors Costa; Andrea Patriarca; Carlos Jiménez-Vicente; Davide Rossi; Emili Montserrat
Journal:  Leukemia       Date:  2021-02-04       Impact factor: 11.528

2.  Efficacy, safety, and quality of life of generic and innovator ibrutinib in Indian CLL patients.

Authors:  Charanpreet Singh; Nishant Jindal; Padma Youron; Pankaj Malhotra; Gaurav Prakash; Alka Khadwal; Arihant Jain; Sreejesh Sreedharanunni; Man Updesh Singh Sachdeva; Shano Naseem; Neelam Varma; Subhash Varma; Deepesh P Lad
Journal:  Indian J Hematol Blood Transfus       Date:  2020-11-13       Impact factor: 0.900

Review 3.  Recent progress of prognostic biomarkers and risk scoring systems in chronic lymphocytic leukemia.

Authors:  Xiaoya Yun; Ya Zhang; Xin Wang
Journal:  Biomark Res       Date:  2020-09-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.